ELUT ELUTIA INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1708527 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.2%
TTM net income YoY305.5%
TTM EPS YoY233.3%
Revenue 3-yr CAGR-26.9%
Net income 3-yr CAGR—
Margins
Gross margin59.0%
Operating margin-279.0%
Net margin546.7%
FCF margin-509.4%
EBITDA margin-265.2%
Returns
ROE—
ROA140.2%
ROIC (approx.)—
Asset turnover0.26x
Leverage & solvency
Liabilities / assets68.2%
Debt / equity0.53x
Current ratio2.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.91x
Accruals ratio267.1%
Payout ratio—
Capex / revenue14.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $12.29M | $14.47M |
| Cost of revenue | $5.70M | $7.75M |
| Gross profit | $6.60M | $6.71M |
| R&D expense | $4.16M | $3.00M |
| SG&A expense | $15.08M | $18.07M |
| Operating income | -$26.91M | -$30.71M |
| Interest expense | — | $4.78M |
| Pretax income | -$15.86M | -$45.34M |
| Income tax | $13,000 | $7,000 |
| Net income | $53.38M | -$53.95M |
| EBITDA | -$24.13M | -$27.26M |
| EPS (basic) | 1.29 | -1.86 |
| EPS (diluted) | 0.87 | -1.86 |
| Weighted avg. shares (diluted) | 45.94M | 29.07M |
| Balance sheet | ||
| Cash & equivalents | $36.35M | $13.24M |
| Receivables | $1.73M | $2.28M |
| Inventory | $438,000 | $1.93M |
| Current assets | $55.82M | $26.17M |
| PP&E, net | $2.51M | $671,000 |
| Intangibles | $1.53M | $2.60M |
| Total assets | $62.35M | $36.13M |
| Current liabilities | $25.14M | $37.80M |
| Short-term debt | — | $1.25M |
| Long-term debt | — | $22.60M |
| Total debt | — | $23.85M |
| Total liabilities | $34.68M | $82.39M |
| Shareholders' equity | $27.67M | -$46.26M |
| Net debt | — | $10.61M |
| Cash flow statement | ||
| Operating cash flow | -$44.81M | -$22.66M |
| Capital expenditure | $1.88M | $654,000 |
| Free cash flow | -$46.69M | -$23.31M |
| Investing cash flow | $78.56M | -$474,000 |
| Financing cash flow | -$10.64M | $17.09M |
| Depreciation & amortization | $2.79M | $3.45M |
| Stock-based compensation | $5.21M | $7.89M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.